main visual a man watching devise

Stable Cell Line Development Service for Biopharmaceutical Production

As targeted therapies using biopharmaceuticals are becoming more critical, manufacturing processes that speed up their production efficiently, robustly, and cost-effectively gain more importance in order to support patients globally.
Chitose laboratory’s mission is to create the next-generation biopharmaceutical manufacturing platform centering on our proprietary and uniquely high-performance CHO cells (known as CHO-MK cells), which is reliably applicable to accelerate the development of biopharmaceuticals, reduce the manufacturing costs and contribute to global health care.

High Performance

IgG production in fed-batch bioreactor image
IgG production in fed-batch bioreactor
  • Large amount of antibody production (10 g/L) in 5 days

CHO-MK Host Cell Bank

Host Cell Bank image
  • Applicable for biopharmaceutical production
  • Conditioned to complete serum-free suspension culture
  • Passed viral safety tests
  • Completed Host Cell Bank testing package (CoA)

Benefits of CS CHO™️ Vector

CS CHO™️ Vector image
  • Chitose Laboratory’s original expression vector system
  • Signal nucleotide sequences for high expression utility
  • Expert in the design of nucleotide sequence for high expression in CHO-MK cell

Business Flow

online meeting flow chart
  • Contact us for an online meeting and discuss your needs

CLD Platform

CLD Platform chart
  • CHO-MK Cell and CS CHOTM expression vector system
  • FCM-based enrichment of high-producing stable pool
  • High-fidelity cloning by single-cell sorting
  • Clonality assurance by high resolution imaging system
  • Early-process development using bioreactor

If you have any inquiries about our CLD service and technology, please contact us here.

Company name

Chitose Laboratory Corp.

Location

KSP East 511, 3-2-1 Sakado, Takatsu-ku, Kawasaki, Kanagawa 213-0012, Japan

Establishment

November 2002

Number of employees

Approx. 110 (including executives and part-timers, more than 250 in the entire group)

view more